The potential for these agents in the treatment of patients with advanced cancers, including their incorporation into combination regimens (e.g., PD-1- plus CTLA-4-blocking antibodies), is significant, and further data are eagerly awaited. This evidence concerns the gene CTLA4 and cancer.